A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants

Part of paid clinical trials in Tempe, Arizona.

Sponsor
Incyte Corporation
Study ID
NCT07448155
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • INCA033989 — DRUG
    INCA033989 will be administered at protocol defined dose.

Study Details

This study is being conducted to evaluate the pharmacokinetics, safety, and tolerability of INCA033989 following subcutaneous (SC) or intravenous administration (IV) n healthy adult participants.

Key Dates

Start date
Mar 19, 2026
Status verified
Jun 2026
Primary completion
Oct 19, 2026
Completion
Oct 19, 2026

Study Design

Enrollment
72 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1
    INCA033989 will be administered at protocol defined dose administered as a SC injection.
  • Experimental: Cohort 2
    INCA033989 will be administered at protocol defined dose administered as a SC injection.
  • Experimental: Cohort 3
    INCA033989 will be administered at protocol defined dose administered as an IV infusion.
  • Experimental: Cohort 4
    INCA033989 will be administered at protocol defined dose administered as a SC injection.

Primary Outcome Measure

Pharmacokinetics Parameter: Cmax of INCA33989 following a single SC administration compared with a single IV infusion [ Time Frame: Up to 12 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Celerion Clinical Research UnitTempeArizona85283-

Find similar trials in Tempe, AZ

By research site
Celerion Clinical Research Unit· Tempe, AZ

Related Studies